Provectus Biopharmaceuticals, Inc. (PVCT)
OTCMKTS · Delayed Price · Currency is USD
0.0530
-0.0020 (-3.64%)
Apr 15, 2026, 3:52 PM EST
Provectus Biopharmaceuticals Employees
Provectus Biopharmaceuticals had 6 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$56,018
Profits / Employee
-$905,142
Market Cap
22.27M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 6 | 0 | - |
| Dec 31, 2024 | 6 | 2 | 50.00% |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | 0 | - |
| Dec 31, 2021 | 4 | 2 | 100.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| HOOKIPA Pharma | 87 |
| Oncotelic Therapeutics | 26 |
| Zeo ScientifiX | 20 |
| Harvard Apparatus Regenerative Technology | 8 |
| Inhibitor Therapeutics | 8 |
| Anebulo Pharmaceuticals | 3 |
| Vicapsys Life Sciences | 2 |
Provectus Biopharmaceuticals News
- 14 days ago - Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment - GlobeNewsWire
- 6 months ago - Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy - GlobeNewsWire
- 7 months ago - Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer - GlobeNewsWire
- 10 months ago - Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer - GlobeNewsWire
- 11 months ago - Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders - GlobeNewsWire
- 1 year ago - Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye Drugs - GlobeNewsWire
- 1 year ago - Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call - GlobeNewsWire
- 2 years ago - Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines - GlobeNewsWire